Two of the most well-studied checkpoint molecules include cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1).13 Ipilimumab, which targets CTLA-4, was the first ICI licensed for use in cancer patients, in the treatment of metastatic melanoma.14 The first two PD-1 ICIs to be approved were pembrolizumab and nivolumab, which show similar efficacy and longstanding results as ipilimumab. This evidence concerns the gene CTLA4 and metastatic melanoma.